📣 VC round data is live. Check it out!
Alfresa Holdings Valuation Multiples
Discover Alfresa Holdings' revenue and EBITDA valuation multiples, acquisitions, and investment history.
Alfresa Holdings Overview
About Alfresa Holdings
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
Founded
2003
HQ
Employees
15.5K
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trial
Alfresa Holdings Financials
Alfresa Holdings reported last 12-month revenue of $20B and EBITDA of $324M.
In the same LTM period, Alfresa Holdings generated $324M in EBITDA and $244M in net income.
Alfresa Holdings P&L
In the most recent fiscal year, Alfresa Holdings reported revenue of $19B and EBITDA of $341M.
Alfresa Holdings is profitable as of last fiscal year, with gross margin of 7%, EBITDA margin of 2%, and net margin of 1%.
Financial data powered by Morningstar, Inc.
Alfresa Holdings Stock Performance
Alfresa Holdings has current market cap of $2B, and enterprise value of $2B.
Alfresa Holdings' stock price is $13.76.
Alfresa Holdings has an EPS (earnings per share) of $0.94.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.2% | - | - | - | $0.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlfresa Holdings Valuation Multiples
Alfresa Holdings trades at 0.1x EV/Revenue multiple, and 4.7x EV/EBITDA.
Alfresa Holdings Financial Valuation Multiples
As of June 5, 2026, Alfresa Holdings has market cap of $2B and EV of $2B.
Alfresa Holdings has a P/E ratio of 10.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alfresa Holdings Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alfresa Holdings Margins & Growth Rates
Alfresa Holdings grew revenue by 6% but EBITDA decreased by 5% in the last fiscal year.
In the most recent fiscal year, Alfresa Holdings reported gross margin of 7%, EBITDA margin of 2%, and net margin of 1%.
Alfresa Holdings Margins
Alfresa Holdings Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Alfresa Holdings Operational KPIs
Alfresa Holdings' revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.1M for the same period.
Alfresa Holdings' Rule of 40 is 4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alfresa Holdings' Rule of X is 7% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Alfresa Holdings Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Alfresa Holdings competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Alfresa Holdings
Alfresa Holdings has acquired 2 companies to date.
Last acquisition by Alfresa Holdings was on May 26th 2026. Alfresa Holdings acquired Nagashima Medical Instruments for undisclosed valuation.
Latest Acquisitions by Alfresa Holdings
| Description | Nagashima Medical Instruments is a Japanese manufacturer of medical devices for otolaryngology and head and neck surgery. | Sansho Co is a Tokyo-headquartered pharmaceutical developer and manufacturer specializing in generic drugs and over-the-counter medications. The company produces treatments for gastrointestinal disorders, pain relief, and dermatological conditions under brands like Sannova. It supplies products to pharmacies and hospitals across Japan. |
| HQ Country |  | |
| HQ City | Tokyo | Gunma |
| Deal Date | 26 May 2026 | 30 Apr 2016 |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Alfresa Holdings acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by Alfresa Holdings
Alfresa Holdings has invested in 6 companies to date.
Latest investment by Alfresa Holdings was on March 8th 2026. Alfresa Holdings invested in Alfenax Biologics in their Strategic investment round.
Latest Investments by Alfresa Holdings
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>){kind=small} Alfenax Biologics | |||||
| Description | Alfenax Biologics is a Japanese joint venture formed by Mycenax Biotech, Alfresa Holdings, Kidswell Bio Corporation, and Chiome Bioscience for biologics manufacturing. | Gexval is a South Korea-based drug discovery company targeting rare and orphan diseases. The firm develops small molecule therapeutics through proprietary screening platforms, aiming to deliver affordable treatments for unmet medical needs in oncology and neurology. | Medcom is a Japanese venture firm bridging medical, healthcare, and IT sectors. The company plans, develops, sells, and maintains nibyo mobile, a smartphone application dedicated to medical institutions for streamlined operations and data management. | - | |
| HQ Country | | | | | |
| HQ City | Tokyo | Fujisawa | Tokyo | - | |
| Deal Date | 8 Mar 2026 | 16 Jan 2025 | 8 Jun 2022 | 4 Jan 2021 | |
| Round | Strategic investment | Series C | Series B | Series B | |
| Raised | undisclosed | $2M | $8M | $13M | |
| Investors | Alfresa Holdings; Chiome Bioscience; Mycenax Biotech; Kidswell Bio | Alfresa Holdings | Alfresa Holdings; Global Catalyst Partners Japan; ITOCHU Techno-Solutions Corporation; UTEC-The University of Tokyo Edge Capital Partners | Alfresa Holdings; Dai-ichi Life; Eight Roads Ventures; F-Prime; Japan Lifeline; KSP; MAKOTO Capital; Sony Innovation Fund; Tsukuba Exceed Fund; UTEC-The University of Tokyo Edge Capital Partners | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Alfresa Holdings investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alfresa Holdings
| When was Alfresa Holdings founded? | Alfresa Holdings was founded in 2003. |
| Where is Alfresa Holdings headquartered? | Alfresa Holdings is headquartered in Japan. |
| How many employees does Alfresa Holdings have? | As of today, Alfresa Holdings has over 15K employees. |
| Is Alfresa Holdings publicly listed? | Yes, Alfresa Holdings is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Alfresa Holdings? | Alfresa Holdings trades under 2784 ticker. |
| When did Alfresa Holdings go public? | Alfresa Holdings went public in 2003. |
| Who are competitors of Alfresa Holdings? | Alfresa Holdings main competitors include |
| What is the current market cap of Alfresa Holdings? | Alfresa Holdings' current market cap is $2B. |
| What is the current revenue of Alfresa Holdings? | Alfresa Holdings' last 12 months revenue is $20B. |
| What is the current revenue growth of Alfresa Holdings? | Alfresa Holdings revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Alfresa Holdings? | Current revenue multiple of Alfresa Holdings is 0.1x. |
| What is the current EBITDA of Alfresa Holdings? | Alfresa Holdings' last 12 months EBITDA is $324M. |
| What is Alfresa Holdings' EBITDA margin? | Alfresa Holdings' last 12 months EBITDA margin is 2%. |
| What is the current EV/EBITDA multiple of Alfresa Holdings? | Current EBITDA multiple of Alfresa Holdings is 4.7x. |
| What is the current FCF of Alfresa Holdings? | Alfresa Holdings' last 12 months FCF is $180M. |
| What is Alfresa Holdings' FCF margin? | Alfresa Holdings' last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Alfresa Holdings? | Current FCF multiple of Alfresa Holdings is 8.4x. |
| How many companies Alfresa Holdings has acquired to date? | As of June 2026, Alfresa Holdings has acquired 2 companies. |
| What was the largest acquisition by Alfresa Holdings? | None of the M&A deals Alfresa Holdings has completed have disclosed valuations. |
| What companies Alfresa Holdings acquired? | Alfresa Holdings acquired Sansho Co and Nagashima Medical Instruments. |
| In how many companies Alfresa Holdings has invested to date? | As of June 2026, Alfresa Holdings has invested in 6 companies. |
| What was the last Alfresa Holdings investment? | On 8th March 2026 Alfresa Holdings invested in Alfenax Biologics, participating in a Strategic investment round, alongside Chiome Bioscience, Mycenax Biotech, and Kidswell Bio. |
| In what companies Alfresa Holdings invested in? | Alfresa Holdings invested in Metcela, Medcom, Integrity Healthcare, Quantum Operation, Gexval, and Alfenax Biologics. |
Lists including Alfresa Holdings
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.